Skip to main content
Fig. 9 | BMC Pharmacology and Toxicology

Fig. 9

From: Mitochondrial targeted antioxidants, mitoquinone and SKQ1, not vitamin C, mitigate doxorubicin-induced damage in H9c2 myoblast: pretreatment vs. co-treatment

Fig. 9

Effects of co-treatment or pretreatment of SKQ1 or MitoQ on Dox-induced increase in mitochondrial SO levels. Co-treatment (A) or pretreatment (B) of SKQ1 and MitoQ significantly attenuated Dox-induced mitochondrial SO levels. Pretreatment (C-D) showed better reduction in mitochondrial SO levels than co-treatment only at a higher dose (1–5 μM). Moreover, MitoQ exerted better reduction than SKQ1 at most doses. **p < 0.01 vs Dox; #p < 0.05, ##p < 0.01 vs MitoQ or SKQ1, respectively

Back to article page